Empowering Consumers Hurt by Big Businesses

Local (415) 319-8833
Toll Free (855) 534-0061

Blog Posts in February, 2014

  • FDA EXAMINES HEART FAILURE RISK WITH DIABETES DRUG

    The FDA has recently issued a safety communication regarding a possible link between saxagliptin and heart failure. Saxagliptin, marketed as Onglyza and Kombiglyze XR by Bristol-Myers Squibb, is a drug used to treat type 2 diabetes. The safety communication was prompted by a study published in the New England Journal of Medicine which found use of saxagliptin was associated with increased rate of ...
    Continue Reading
  • HARVARD MEN'S HEALTH WATCH WARNS OF CARDIAC RISKS WITH TESTOSTERONE THERAPY

    The most recent issue of Harvard Men's Health Watch discusses the safety and risks associated with testosterone therapy (TT). The newsletter notes that millions of Americans undergo testosterone therapy, enticed by the myriad promises of lifestyle improvements offered by the "ongoing pharmaceutical marketing blitz." However, there are "legitimate safety concerns linger[ing]", such as new evidence ...
    Continue Reading
  • THE ENDOCRINE SOCIETY CALLS FOR REEVALUATION OF TESTOSTERONE THERAPY RISKS

    The Endocrine Society has issued a statement highlighting the need for robust evaluation of the risks associated with testosterone therapy (TT). In it, the Society recommends that "patients should be made aware of the potential risk of cardiovascular events in middle-aged and older men who are taking or considering testosterone therapy for age-related decline in testosterone levels and symptoms." ...
    Continue Reading
  • FDA Evaluating the Risk of Heart Attack, Stroke and Death Following Testosterone Therapy in Men

    A recent safety announcement issued by the FDA warned of safety risks associated with testosterone therapy (TT). In particular, the "FDA is investigating the risk of stroke, heart attack, and death in men taking FDA-approved testosterone products." Two recent publications have prompted the FDA "to reassess the cardiovascular safety" of TT. A November 2013 publication reported 29% increase in the ...
    Continue Reading
  • TESTOSTERONE STUDY OBSERVED DISCREPANCY IN RISK REPORTED BY INDUSTRY FUNDED TRIALS COMPARED TO NON-INDUSTRY FUNDED TRIALS

    A recent study published in 2013 warned that the risk of cardiovascular events is increased in men who have been prescribed testosterone therapy. Such cardiovascular events included heart attacks, congestive heart failures, coronary artery diseases, arrhythmias, and other cardiovascular disorders. In particular, this robust systematic review found the risk was increased by 54% for cardiovascular ...
    Continue Reading
Page 1 of 1